Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Armata Pharmaceuticals (ARMP) Current Deferred Revenue (2016 - 2018)

Quarterly results put Current Deferred Revenue at $335000.0 for Q4 2018, changed N/A from a year ago — trailing twelve months through Dec 2018 was $335000.0 (changed N/A YoY), and the annual figure for FY2018 was $335000.0, changed.

Armata Pharmaceuticals has reported Current Deferred Revenue over the past 6 years, most recently at $335000.0 for Q4 2018.

  • Current Deferred Revenue reached $335000.0 in Q4 2018 per ARMP's latest filing, up from $20000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $350000.0 in Q2 2015 and bottomed at $18000.0 in Q3 2016.
  • Median Current Deferred Revenue over the past 5 years was $142000.0 (2015), compared with a mean of $177666.7.
  • The largest annual shift saw Current Deferred Revenue crashed 92.71% in 2016 before it soared 34.88% in 2017.
  • Over 5 years, Current Deferred Revenue stood at $244000.0 in 2014, then grew by 0.41% to $245000.0 in 2015, then plummeted by 92.65% to $18000.0 in 2016, then grew by 11.11% to $20000.0 in 2017, then skyrocketed by 1575.0% to $335000.0 in 2018.
  • Business Quant data shows Current Deferred Revenue for ARMP at $335000.0 in Q4 2018, $20000.0 in Q3 2017, and $58000.0 in Q2 2017.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn -
5 Akari Therapeutics 605.66 Bn 605.66 Bn -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn
8 Evaxion A 65.12 Bn 65.10 Bn -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn
10 Armata Pharmaceuticals 301.92 Mn 297.17 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2018 335,000.00
Sep 30, 2017 20,000.00
Jun 30, 2017 58,000.00
Mar 31, 2017 86,000.00
Sep 30, 2016 18,000.00
Jun 30, 2016 43,000.00